Sign Out
Animal trials report evidence of possible teratogenic effects. There are no related data on use in man.
Women of child-bearing age should only receive ursodeoxycholic acid if they are using reliable contraceptive methods. It should be ensure that the patient is not pregnant before commencing therapy.
For reasons of safety, it is advisable not the use Ursofalk during the first three months of pregnancy and during lactation.
